GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated November 12, 2024, serves as a transaction notification for Persons Discharging Managerial Responsibilities (PDMRs). The report details share acquisitions executed on November 11, 2024, on the London Stock Exchange (XLON) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports on specific insider trading transactions. The transaction price for all reported acquisitions was £13.9893 per Ordinary Share.
Material Changes and Transaction Details
The filing reports the following acquisitions of Ordinary Shares (ISIN: GB00BN7SWP63) by senior executives:
- Emma Walmsley (CEO): Acquired 18 shares (9 partnership, 9 matching).
- Julie Brown (CFO): Acquired 16 shares (8 partnership, 8 matching).
- James Ford (SVP, Group General Counsel): Acquired 18 shares (9 partnership, 9 matching).
- Sally Jackson (SVP, Global Communications): Acquired 18 shares (9 partnership, 9 matching).
- David Redfern (President, Corporate Development): Acquired 18 shares (9 partnership, 9 matching).
- Regis Simard (President, Global Supply Chain): Acquired 18 shares (9 partnership, 9 matching).
- Philip Thomson (President, Global Affairs): Acquired 18 shares (9 partnership, 9 matching).
- Deborah Waterhouse (CEO, ViiV Healthcare): Acquired 18 shares (9 partnership, 9 matching).
- Victoria Whyte (Company Secretary): Acquired 18 shares (9 partnership, 9 matching).
All transactions were classified as "Initial notification" and involved the acquisition of shares under the Share Reward Plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of specific share transactions only.
Investor Verification Checklist
- Verify the total number of shares acquired by each PDMR against the company's latest insider trading reports.
- Confirm the share price of £13.9893 aligns with the market price on the London Stock Exchange for November 11, 2024.
- Review the terms of the GSK Share Reward Plan to understand the mechanics of "partnership" and "matching" shares.
- Note that this filing contains no operational or financial performance data; refer to Form 20-F for comprehensive financial metrics.